<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="36543">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02630797</url>
  </required_header>
  <id_info>
    <org_study_id>BB2015</org_study_id>
    <nct_id>NCT02630797</nct_id>
  </id_info>
  <brief_title>Effect of Blueberries on Bone Turnover</brief_title>
  <official_title>Berries and Bones:The Effect of Polyphenolic Metabolites From Blueberries on Bone Turnover</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Purdue University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Purdue University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study uses a bone labeled calcium tracer methodology to compare the dose response
      effect of blueberry consumption on calcium retention and bone loss. Post menopausal women
      will receive food or beverage products containing freeze dried blueberries over a 50 day
      period equivalent to low (0.75 cups), medium (1.5 cups), and high (3 cups) of fresh berries.
      The hypothesis is that the polyphenolic content of higher doses of blueberries will reduce
      calcium loss from bones.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will be dosed with Ca-41, a rare long lived radioisotope. After equilibration
      in the bone tissues (150 days) subjects will be assigned to one of six randomization schemes
      all of which begin (day 0) with a 50 day baseline period during which 24 h urine will be
      collected every 10 days. Following the baseline period subjects will be randomized to one of
      three doses of blueberries equivalent to 0.75 (low), 1.5 (medium), and 3 cups (high) of
      blueberries per day. In a crossover design each participant will complete three 50 d
      intervention phases(low, medium, high dose of berries) in randomized order, each followed by
      a 50 day washout phase. Each dose will be provided as freeze dried blueberry powder in 2-4
      food products or beverages per day. The dose response effect of continuous blueberry
      consumption over a 50 day period on bone resorption in healthy post-menopausal women will be
      studied by measuring the loss of Ca41 in the urine using Accelerator Mass Spectrometry..
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double Blind (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ca-41 / Ca ratio in 24 hour urinary excretion to estimate calcium loss from bone</measure>
    <time_frame>From beginning of baseline phase (day 1) to the end of the 3rd washout phase (day 350)</time_frame>
    <description>24 h urine will be collected approximately every 12-13 days during baseline(days1-50), and every 10 days during the low, medium, and high interventions in randomized order(days 50-100, 150-200, and 250-300). During washout phases urine will be collected every 25 days(days 100-150, 200-250, and 300-350).Ca41/Ca ratios will be measured by Accelerator Mass Spectrometry.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fasting blood and urine analysis of blueberry polyphenolic metabolites</measure>
    <time_frame>Days 50, 100, 200, and 300</time_frame>
    <description>Fasting blood and urine will be collected at the end of baseline(day 50), and at the end of the low, medium, and high (randomized order)blueberry interventions. (days 100, 200, and 300). Polyphenolic metabolites will be measured by LC-MSMS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum biochemical markers of bone metabolism: calcium</measure>
    <time_frame>Days 50, 100, 200, and 300</time_frame>
    <description>Fasting blood and urine will be collected at the end of baseline(day 50), and at the end of the low, medium, and high (randomized order)blueberry interventions. (days 100, 200, and 300). Serum calcium will be measured by Atomic Absorption Spectrophotometry..</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum biochemical markers of bone metabolism:Insulin Dependent Growth Factor-1</measure>
    <time_frame>Days 50, 100, 200, and 300</time_frame>
    <description>Fasting blood and urine will be collected at the end of baseline(day 50), and at the end of the low, medium, and high (randomized order)blueberry interventions. (days 100, 200, and 300). IGF-1 will be measured by ELISA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum biochemical markers of bone metabolism: Osteoprotegrin</measure>
    <time_frame>Days 50, 100, 200, and 300</time_frame>
    <description>Fasting blood and urine will be collected at the end of baseline(day 50), and at the end of the low, medium, and high (randomized order)blueberry interventions. (days 100, 200, and 300). Osteoprotegrin will be measured by ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum biochemical markers of bone metabolism: RANK ligand</measure>
    <time_frame>Days 50, 100, 200, and 300</time_frame>
    <description>Fasting blood and urine will be collected at the end of baseline(day 50), and at the end of the low, medium, and high (randomized order)blueberry interventions. (days 100, 200, and 300). RANK ligand will be measured by ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum biochemical markers of bone metabolism: 25(OH) Vitamin D</measure>
    <time_frame>Days 50, 100, 200, and 300</time_frame>
    <description>Fasting blood and urine will be collected at the end of baseline(day 50), and at the end of the low, medium, and high (randomized order)blueberry interventions. (days 100, 200, and 300). 25(OH) Vitamin D will be measured by LC/MS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum biochemical markers of bone metabolism: sclerostin</measure>
    <time_frame>Days 50, 100, 200, and 300</time_frame>
    <description>Fasting blood and urine will be collected at the end of baseline(day 50), and at the end of the low, medium, and high (randomized order)blueberry interventions. (days 100, 200, and 300). Sclerostin will be measured by ELISA</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">22</enrollment>
  <condition>Osteoporosis, Postmenopausal</condition>
  <arm_group>
    <arm_group_label>Blueberry baseline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>No blueberry products provided as part of the usual dietary intake</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Blueberry Low</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Products containing equivalent of 0.75 cups of blueberries per day provided as part of usual dietary intake for 50 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Blueberry Medium</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Products containing equivalent of 1.5 cups of blueberries per day provided as part of usual dietary intake for 50 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Blueberry High</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Products containing equivalent of 3 cups of blueberries per day provided as part of usual dietary intake for 50 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Blueberry Baseline</intervention_name>
    <description>Before the beginning of the study eligible participants will receive a radioactive tracer, Ca-41, by iv infusion. 150 days will be required for equilibration in the body i.e. elimination of the tracer from soft tissue and deposition in the bone. After equilibration, a baseline phase of 50 days will occur during which no blueberry products will be consumed in addition to usual dietary intake</description>
    <arm_group_label>Blueberry baseline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Blueberry low</intervention_name>
    <description>Food products will be provided daily for 50 days which contain dried blueberry powder equivalent to a total of 0.75 cups fresh blueberries</description>
    <arm_group_label>Blueberry Low</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Blueberry Medium</intervention_name>
    <description>Food products will be provided daily for 50 days which contain dried blueberry powder equivalent to a total of 1.5 cups fresh blueberries</description>
    <arm_group_label>Blueberry Medium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Blueberry High</intervention_name>
    <description>Food products will be provided daily for 50 days which contain dried blueberry powder equivalent to a total of 3 cups blueberries</description>
    <arm_group_label>Blueberry High</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female subject is healthy

          -  Subject is &gt; 4 years past the onset of natural menopause or total hysterectomy

        Exclusion Criteria:

          -  History of metabolic bone disease or low trauma fractures

          -  Subject taking osteoporosis treatment drugs or glucocorticoids within 6 months of the
             beginning of the study

          -  Subjects taking bisphosphonates within 2 years of the study

          -  History of cancer, thromboembolisms, clotting disorders, uncontrolled hypertension,
             abnormal thyroid function, malabsorption syndrome, seizure disorders, or heart attack

          -  BMI &gt; 35 kg/m2,

          -  Subjects who will not comply with study interventions

          -  Subjects who will not stop taking natural product supplements of their own selection.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Connie M Weaver, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Nutrition Science, Purdue University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Berdine Martin, PhD</last_name>
    <phone>765-494-6559</phone>
    <email>bmartin1@purdue.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Connie M Weaver, PhD</last_name>
    <phone>765-494-8237</phone>
    <email>weavercm@purdue.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Nutrition Science Purdue University</name>
      <address>
        <city>West Lafayette</city>
        <state>Indiana</state>
        <zip>47907-2059</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Chen JR, Lazarenko OP, Wu X, Kang J, Blackburn ML, Shankar K, Badger TM, Ronis MJ. Dietary-induced serum phenolic acids promote bone growth via p38 MAPK/Î²-catenin canonical Wnt signaling. J Bone Miner Res. 2010 Nov;25(11):2399-411. doi: 10.1002/jbmr.137.</citation>
    <PMID>20499363</PMID>
  </reference>
  <reference>
    <citation>Devareddy L, Hooshmand S, Collins JK, Lucas EA, Chai SC, Arjmandi BH. Blueberry prevents bone loss in ovariectomized rat model of postmenopausal osteoporosis. J Nutr Biochem. 2008 Oct;19(10):694-9. doi: 10.1016/j.jnutbio.2007.09.004. Epub 2008 Mar 6.</citation>
    <PMID>18328688</PMID>
  </reference>
  <reference>
    <citation>Weaver CM, Martin BR, Jackson GS, McCabe GP, Nolan JR, McCabe LD, Barnes S, Reinwald S, Boris ME, Peacock M. Antiresorptive effects of phytoestrogen supplements compared with estradiol or risedronate in postmenopausal women using (41)Ca methodology. J Clin Endocrinol Metab. 2009 Oct;94(10):3798-805. doi: 10.1210/jc.2009-0332. Epub 2009 Jul 7.</citation>
    <PMID>19584189</PMID>
  </reference>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 19, 2016</lastchanged_date>
  <firstreceived_date>December 7, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Purdue University</investigator_affiliation>
    <investigator_full_name>Berdine Martin</investigator_full_name>
    <investigator_title>Research Scientist - Study Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Osteoporosis, Postmenopausal</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
